PIP4K2A

PIP4K2A is a lipid kinase that phosphorylates phosphatidylinositol-5-phosphate to generate PI(4,5)P2 at discrete membrane compartments, thereby controlling membrane contacts, ion channel and transporter activity, and PI3K signaling (PMID:29353240, PMID:18545987). At the peroxisomal membrane its PI(4,5)P2 output sustains synaptotagmin-VII-bridged lysosome–peroxisome contacts and limits lysosomal cholesterol accumulation, with kinase-active enzyme required for rescue (PMID:29353240). In neurons, PIP4K2A-derived PI(4,5)P2 activates heteromeric KCNQ2/3 and KCNQ3/5 M channels and enhances the membrane abundance and currents of the EAAT3 glutamate transporter and the GluA1 AMPA receptor (PMID:18545987, PMID:19644675, PMID:24389605). The schizophrenia-associated N251S substitution is kinase-inactive and abolishes these activities, acting in a dominant-inhibitory manner on EAAT3 (PMID:18545987, PMID:19644675). Beyond lipid signaling, PIP4K2A behaves as a context-dependent regulator of the PI3K pathway by promoting proteasomal degradation of the p85 regulatory subunit, suppressing clonogenic and tumor growth in PTEN-deficient glioblastoma (PMID:30898893), yet it is also required for the leukemia-initiating potential of AML cells, where its loss triggers CDKN1A/CDKN1B accumulation, G1 arrest and mTOR-dependent apoptosis (PMID:24681948). PIP4K2A additionally phosphorylates MIF at serine 91 to promote 14-3-3ζ binding and MIF nuclear translocation driving ciliogenesis (PMID:38052787), and carries a conserved, kinase-independent RNA-binding activity (PMID:34124142). A crystal structure of PIP4K2A bound to an inhibitor defines a water-mediated contact in the specificity-pocket roof that underlies isoform-selective inhibitor design (PMID:42117906); selective inhibitors engage the enzyme in cells but do not reproduce the antiproliferative phenotype attributed to PIP4K2A loss, showing kinase inhibition alone is insufficient (PMID:34699202).

1. 2005 Low

   Established a candidate transcriptional-regulatory mechanism linking PIP4K2A to brain biology by showing a promoter variant alters nuclear-protein binding.

   Evidence SSCP screening and EMSA of the -1007C→T promoter variant

   PMID:16094259

   Open questions at the time

   • The brain-specific nuclear protein was not identified
   • Single EMSA without functional reporter validation
   • No link to PIP4K2A expression level in vivo
2. 2008 High

   Demonstrated that PIP4K2A kinase activity controls neuronal M-channel function through PI(4,5)P2, and that the disease-associated N251S mutation is a loss-of-function allele.

   Evidence Xenopus oocyte voltage clamp with PI(4,5)P2 injection, PIP2 scavenger, and WT vs N251S comparison

   PMID:18545987

   Open questions at the time

   • Selectivity for heteromeric vs homomeric KCNQ channels not mechanistically explained
   • Endogenous neuronal relevance not tested
3. 2009 Medium

   Extended PIP4K2A's regulation of membrane proteins to the EAAT3 glutamate transporter and showed N251S acts dominant-negatively.

   Evidence Oocyte and HEK expression, voltage clamp, membrane EAAT3 imaging, WT vs N251S

   PMID:19644675

   Open questions at the time

   • Mechanism of dominant inhibition not resolved
   • No endogenous neuronal validation
4. 2014 Medium

   Defined PIP4K2A as required for AML clonogenic and leukemia-initiating potential, placing its loss-of-function phenotype downstream through CDK inhibitors and mTOR.

   Evidence RNAi knockdown, cell cycle/apoptosis flow cytometry, CDKN1A/CDKN1B and mTOR western blot, MLL-AF9 model

   PMID:24681948

   Open questions at the time

   • Direct lipid substrate link to mTOR not established
   • Distinction from kinase-independent functions untested
5. 2014 Medium

   Showed PIP4K2A enhances AMPA receptor (GluA1) currents via PI(4,5)P2 binding to a defined GluA1 C-terminal region.

   Evidence Oocyte electrophysiology, GluA1 alanine scan, PIP strip assay, membrane abundance western blot

   PMID:24389605

   Open questions at the time

   • In vivo synaptic relevance not addressed
   • Single expression-system context
6. 2018 High

   Localized PIP4K2A kinase activity to the peroxisomal membrane and connected its PI(4,5)P2 output to lysosome–peroxisome contacts and cholesterol handling.

   Evidence RNAi, peroxisome-targeted kinase-active rescue, in vitro contact reconstitution with recombinant protein, microscopy

   PMID:29353240

   Open questions at the time

   • How PIP4K2A is targeted to peroxisomes not defined
   • Direct PI(4,5)P2 sensing by synaptotagmin VII not shown
7. 2019 Medium

   Identified PIP4K2A as a tumor suppressor in PTEN-deficient glioblastoma that lowers PI3K signaling by promoting proteasomal degradation of p85.

   Evidence In vivo RNAi PDX screen, overexpression/knockdown, proteasome inhibitor assays, clonogenic and xenograft assays

   PMID:30898893

   Open questions at the time

   • Mechanism inferred from protein levels rather than reconstituted degradation
   • Direct PIP4K2A-p85 contact not biochemically defined
8. 2021 Medium

   Uncovered a kinase-independent, evolutionarily conserved RNA-binding activity of PIP4K2A and its import into apicomplexan parasites.

   Evidence RNA-binding assays with kinase-dead mutants, parasite import assays, cross-species comparison

   PMID:34124142

   Open questions at the time

   • RNA targets in the human cell not defined
   • Functional consequence of RNA binding unresolved
9. 2021 Medium

   Established that selective kinase inhibition is insufficient to reproduce the antiproliferative effect of PIP4K2A loss in p53-deficient cells, dissociating phenotype from catalytic activity.

   Evidence HTS, structure-based optimization, CETSA target engagement, antiproliferation assays

   PMID:34699202

   Open questions at the time

   • Whether non-catalytic functions drive the phenotype not tested
   • No genetic vs pharmacologic reconciliation
10. 2023 Medium

    Defined a substrate-level signaling role: PIP4K2A phosphorylates MIF at S91 to promote 14-3-3ζ binding, MIF nuclear translocation and ciliogenesis.

    Evidence Co-IP, in vitro kinase assay, S91 mutagenesis, cilia confocal imaging, gene expression

    PMID:38052787

    Open questions at the time

    • Relationship between protein-kinase and lipid-kinase activities unclear
    • Direct ciliogenesis gene targets of nuclear MIF not detailed
11. 2023 Medium

    Linked alternative splicing of PIP4K2A (the PIP4K2A-S isoform) to PI3K activation via p85 stabilization in hepatocellular carcinoma, in apparent opposition to its p85-degrading role.

    Evidence SLC27A5/IGF2BP3 reciprocal Co-IP, isoform RT-PCR, p85 western blot, AAV and RNA decoy rescue

    PMID:38059827

    Open questions at the time

    • Mechanistic basis for opposing p85 effects across isoforms not resolved
    • Isoform-specific structural difference not defined
12. 2023 Medium

    Identified a gain-of-function S316R mutation that stabilizes PIP4K2A and raises kinase activity, upregulating β-globin and impairing erythroid differentiation.

    Evidence Patient mutation, in vitro kinase and stability assays, HUDEP-2 functional experiments, family analysis

    PMID:37423903

    Open questions at the time

    • Pathway linking kinase activity to β-globin regulation not defined
    • Single-family genetic evidence
13. 2026 High

    Provided structural determinants of isoform-selective inhibition, defining a water-mediated specificity-pocket interaction distinguishing PIP4K2A from PIP4K2B.

    Evidence X-ray crystallography of PIP4K2A-inhibitor complex with comparative analysis

    PMID:42117906

    Open questions at the time

    • No catalytic-mechanism or substrate-bound structure described
    • Functional consequence of selective inhibition not addressed

• How PIP4K2A's lipid-kinase, protein-kinase, and RNA-binding activities are coordinated within a cell, and which activity drives each disease phenotype, remains unresolved.
• No unified model separating catalytic from non-catalytic functions
• Endogenous compartment-specific substrate maps absent
• Reconciliation of opposing roles in PI3K signaling not achieved